ReviewStem cell research & therapy2026
Exosome-derived LncRNAs in bone remodeling: recent advances and future directions for bone disease therapy.
Review in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundExosomes derived from various cellular sources play a pivotal role in mediating and regulating bone and cartilage regeneration for conditions such as bone defects, fractures, cartilage repair, osteoporosis, and osteoarthritis. MAINTEXT: As essential intercellular communication vehicles, exosomes transmit long non-coding RNAs (lncRNAs) to modulate cellular behaviors in the bone microenvironment, which has been a central focus of contemporary research.This review consolidates existing evidence on exosome-derived lncRNAs in bone remodeling, revealing their regulatory roles through signaling pathway networks on osteoclasts, osteoblasts, and related bone/cartilage lineage cells, including mesenchymal stem cells, chondrocytes, and osteoclasts. Exosome-encapsulated lncRNAs that regulate osteogenic differentiation of bone marrow mesenchymal stem cells, osteoclast activity, bone-vascular coupling, and bone metastasis show promise as minimally invasive biomarkers for diagnosis, risk stratification, and therapeutic monitoring of bone metabolic disorders.
conclusionMoreover, harnessing exosomes as natural, engineerable delivery vehicles can advance the development of bone-targeted, precise, and low-toxicity therapeutic strategies to complement existing pharmacologic and regenerative treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.